Literature DB >> 6271273

"Enterolglucagon': a specific effect on gastric glands isolated from the rat fundus. Evidence for an "oxyntomodulin' action.

D Bataille, C Gespach, A M Coudray, G Rosselin.   

Abstract

A newly isolated porcine glucagon-like biologically active intestinal peptide ("enteroglucagon') has been tested for its ability to stimulate the cyclic AMP system present in different tissue preparations from the rat: membranes prepared from liver or from isolated fundic glands as well as intact glands isolated from either the fundus or the antrum. Enteroglucagon (EG) was about 10 times less potent than pancreatic glucagon (G) in liver membranes, whereas it was about 20 times more potent than G in fundic membranes as well as in fundic glands, where it acts at doses as low as 3 X 10(-10) M. EG and G were practically ineffective in antral glands. It is concluded that EG is an "under-glucagon' in rat liver, whereas it is a "super-glucagon' in rat fundic glands. Accordingly, we propose to call this peptide "oxyntomodulin'.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271273     DOI: 10.1007/bf01117012

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  10 in total

Review 1.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 2.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

3.  Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty.

Authors:  J M Kellum; J F Kuemmerle; T M O'Dorisio; P Rayford; D Martin; K Engle; L Wolf; H J Sugerman
Journal:  Ann Surg       Date:  1990-06       Impact factor: 12.969

Review 4.  Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis.

Authors:  Charlotte X Dong; Patricia L Brubaker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-02       Impact factor: 46.802

5.  Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions.

Authors:  B Schjoldager; P E Mortensen; J Myhre; J Christiansen; J J Holst
Journal:  Dig Dis Sci       Date:  1989-09       Impact factor: 3.199

6.  Can Bayliss and Starling gut hormones cure a worldwide pandemic?

Authors:  R V Scott; T M Tan; S R Bloom
Journal:  J Physiol       Date:  2014-09-12       Impact factor: 5.182

Review 7.  Unraveling oxyntomodulin, GLP1's enigmatic brother.

Authors:  Alessandro Pocai
Journal:  J Endocrinol       Date:  2012-09-27       Impact factor: 4.286

Review 8.  Proglucagon-Derived Peptides as Therapeutics.

Authors:  Ryan A Lafferty; Finbarr P M O'Harte; Nigel Irwin; Victor A Gault; Peter R Flatt
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-18       Impact factor: 5.555

Review 9.  Action and therapeutic potential of oxyntomodulin.

Authors:  Alessandro Pocai
Journal:  Mol Metab       Date:  2013-12-14       Impact factor: 7.422

Review 10.  Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity.

Authors:  David C D Hope; Matthew L Vincent; Tricia M M Tan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-08       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.